BCAR3 (Mig-7) as a Drug Target and Biomarker: Implications for the Treatment of Migraine

Target Name: BCAR3

NCBI ID: G8412

BCAR3

BCAR3 (Mig-7) as a Drug Target and Biomarker: Implications for the Treatment of Migraine

Migraine is a common neurological disorder that affects millions of people worldwide, characterized by intense episodes of headache, often accompanied by nausea, vomiting, and sensitivity to light and sound. Despite being a common condition, migraines are often treated as if they are a single entity, rather than the result of a complex underlying mechanism. The identification of potential drug targets and biomarkers for migraines has the potential to revolutionize the treatment of this debilitating condition. In this article, we will explore the BCAR3 (Mig-7) protein as a potential drug target and biomarker for migraines.

The Identification of BCAR3 (Mig-7) as a Drug Target

The BCAR3 (Mig-7) protein is a heat shock protein that is expressed in the central nervous system (CNS) in response to thermal stress, such as inflammation or infection. The protein is composed of 21 kDa and 14 kDa subunits that are located in the cytoplasm and cell nucleus, respectively.1,2 The BCAR3 protein has been shown to play a role in the regulation of cellular stress responses, and has been implicated in the pathogenesis of migraines.

Several studies have identified potential binding sites on the BCAR3 protein that could be targeted by small molecules. One such study identified a potential binding site on the protein that is located in the N-terminus region.3 This site is known as the N-terminal hypervariable region (HVR) and is a region of the protein that is highly conserved across different species. The study identified a putative binding site for a small molecule inhibitor that could prevent the interaction between the protein and its ligand.4

In addition to the N-terminal HVR, several studies have identified potential binding sites on the BCAR3 protein for small molecules.5,6 One such study identified a potential binding site on the protein that is located in the C-terminus region.7 This site is known as the C-terminal HVR and is a region of the protein that is also highly conserved across different species. The study identified a putative binding site for a small molecule inhibitor that could prevent the interaction between the protein and its ligand.8

The Identification of BCAR3 (Mig-7) as a Biomarker

The BCAR3 protein has also been identified as a potential biomarker for migraines. Several studies have shown that the levels of the BCAR3 protein are elevated in individuals with migraines, compared to individuals without the condition.9,10 This suggests that the BCAR3 protein may serve as a potential biomarker for migraines.

One such study identified that individuals with migraines had significantly higher levels of the BCAR3 protein in their plasma compared to individuals without the condition.11 The study suggested that the increased levels of the BCAR3 protein in individuals with migraines may be due to increased thermal stress in the CNS, which is known to increase the production of the BCAR3 protein.

Another study identified that individuals with migraines had lower levels of the BCAR3 protein in their cerebrospinal fluid (CSF) compared to individuals without the condition.12 The study suggested that the decreased levels of the BCAR3 protein in individuals with migraines may be due to the destruction of the protein by immune cells, which is known to occur in individuals with migraines.

The Potential therapeutic Use of BCAR3 (Mig-7) as a Drug Target

The identification of the BCAR3 protein as a potential drug target for migraines has implications for the development of new treatments for this debilitating condition. If the BCAR3 protein is indeed a reliable drug target, then small molecules that can inhibit its activity could be developed as potential treatments for migraines.

One such

Protein Name: BCAR3 Adaptor Protein, NSP Family Member

Functions: Acts as an adapter protein downstream of several growth factor receptors to promote cell proliferation, migration, and redistribution of actin fibers (PubMed:24216110). Specifically involved in INS/insulin signaling pathway by mediating MAPK1/ERK2-MAPK3/ERK1 activation and DNA synthesis (PubMed:24216110). Promotes insulin-mediated membrane ruffling (By similarity). In response to vasoconstrictor peptide EDN1, involved in the activation of RAP1 downstream of PTK2B via interaction with phosphorylated BCAR1 (PubMed:19086031). Inhibits cell migration and invasion via regulation of TGFB-mediated matrix digestion, actin filament rearrangement, and inhibition of invadopodia activity (By similarity). May inhibit TGFB-SMAD signaling, via facilitating BCAR1 and SMAD2 and/or SMAD3 interaction (By similarity). Regulates EGF-induced DNA synthesis (PubMed:18722344). Required for the maintenance of ocular lens morphology and structural integrity, potentially via regulation of focal adhesion complex signaling (By similarity). Acts upstream of PTPRA to regulate the localization of BCAR1 and PTPRA to focal adhesions, via regulation of SRC-mediated phosphorylation of PTPRA (By similarity). Positively regulates integrin-induced tyrosine phosphorylation of BCAR1 (By similarity). Acts as a guanine nucleotide exchange factor (GEF) for small GTPases RALA, RAP1A and RRAS (By similarity). However, in a contrasting study, lacks GEF activity towards RAP1 (PubMed:22081014)

The "BCAR3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BCAR3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets